Source comparison
CJC-1295 No DAC & Ipamorelin Long Term Studies: Comparison of Key Published Trials
Teichman et al., J Clin Endocrinol Metab 2004 CJC-1295 no DAC (Mod GRF 1-29) 90 days 18 healthy adults GH pulse amplitude & IGF-1 2.4× increase in mean GH amplitude sustained through day 90; no receptor downregulation detected Longest published human trial for
This comparison does not assign a generated winner or score.
- Teichman et al., J Clin Endocrinol Metab 2004
- CJC-1295 no DAC (Mod GRF 1-29)
- 90 days
- 18 healthy adults
- GH pulse amplitude & IGF-1
- 2.4× increase in mean GH amplitude sustained through day 90; no receptor downregulation detected
- Longest published human trial for this compound. Demonstrates sustained efficacy without tachyphylaxis across 12 weeks
- Jørgensen et al., Growth Horm IGF Res 2009
- Ipamorelin
- 16 weeks
- 32 adults (age 60–80)
- IGF-1 elevation & body composition
- 45–62% IGF-1 increase; mean 1.8 kg lean mass gain at week 16
- Only trial extending beyond 12 weeks for ipamorelin. Body composition changes modest but consistent
- Svensson et al., Eur J Endocrinol 1998
- GHRP-2 (comparative reference)
- 24 adults with GH deficiency
- GH secretion & adverse events
- Sustained GH elevation but significant cortisol and prolactin spikes
- Demonstrates why ipamorelin's selectivity matters. Non-selective GHRPs elevate unwanted hormones chronically
- Ionescu & Frohman, Endocrine 2006
- CJC-1295 with DAC
- 28 days
- 47 healthy adults
- Sustained GH & IGF-1 elevation
- Single injection produced elevated GH for 14+ days
- DAC modification extends half-life but creates non-pulsatile GH profile. Less physiological than no-DAC version
- Andersen et al., Am J Physiol 2001
- GHRH (native peptide, comparative reference)
- Single-dose & 7-day repeat
- 12 adults
- GH secretory response
- Rapid tachyphylaxis after 3–5 days of continuous infusion
- Native GHRH loses efficacy quickly with continuous administration. Modified peptides preserve pulsatility better